Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Metastasis | Research

Resection of the primary tumor improves the prognosis of gastrointestinal neuroendocrine neoplasms with liver metastases: mutual validation based on SEER database and institutional data

Authors: Yifan Liu, Zhixiong Wang, Qi Lin, Ruizhe Cui, Wei Tang, Guanghua Li, Zhao Wang

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Gastrointestinal Neuroendocrine Neoplasms (GI-NENs) often result in liver metastases, and the role of Primary Tumor Resection (PTR) in managing GI-NENs with liver metastases (GI-NENLM) is still debated. This study aimed to investigate the potential benefits of PTR in treating GI-NENLM by analyzing data from the Surveillance, Epidemiology, and End Results Program (SEER) and the First Affiliated Hospital of Sun Yat-sen University (FAH).

Methods

The SEER Registry 17 database and the FAH clinical pathology database were used to collect clinicopathology data for GI-NENLM diagnosed between 2010 and 2019 and between 2011 and 2022, respectively. Propensity score matching (PSM) was used to match the clinicopathological characteristics of patients from both cohorts. Inverse probability weighting (IPTW) was used to weigh the PTR and non-PTR groups. The primary endpoint was overall survival (OS).

Results

After matching, 155 patients from the SEER database were matched to the FAH cohort. PTR was significantly associated with better prognosis in PSM-matched/unmatched SEER cohorts (P < 0.01) and in the FAH cohort even after eliminating selection bias using IPTW (p < 0.01). Subgroup analysis suggests that the cohort consisting of patients aged 55 years or older, individuals with colorectal primary tumors, those at the T1 disease stage, and those without extrahepatic metastasis may potentially benefit from PTR. Interaction analysis showed no significant interaction between PTR and other clinical and pathological factors except for age.

Conclusion

The employment of PTR in patients with GI-NENLM is significantly correlated with individual survival benefits. We support performing PTR on carefully evaluated patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.CrossRefPubMed Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.CrossRefPubMed
3.
go back to reference Eto K, Yoshida N, Iwagami S, Iwatsuki M, Baba H. Surgical treatment for gastrointestinal neuroendocrine tumors. Ann Gastroenterol Surg. 2020;4(6):652–9.CrossRefPubMedPubMedCentral Eto K, Yoshida N, Iwagami S, Iwatsuki M, Baba H. Surgical treatment for gastrointestinal neuroendocrine tumors. Ann Gastroenterol Surg. 2020;4(6):652–9.CrossRefPubMedPubMedCentral
4.
go back to reference Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, Luo F. Epidemiologic trends of and factors associated with overall survival for patients with Gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Netw Open. 2021;4(9):e2124750.CrossRefPubMedPubMedCentral Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, Luo F. Epidemiologic trends of and factors associated with overall survival for patients with Gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Netw Open. 2021;4(9):e2124750.CrossRefPubMedPubMedCentral
5.
go back to reference Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.CrossRefPubMedPubMedCentral Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.CrossRefPubMedPubMedCentral
6.
go back to reference Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1). Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1).
7.
go back to reference Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139(12):2679–86.CrossRefPubMed Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139(12):2679–86.CrossRefPubMed
8.
go back to reference Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.CrossRefPubMed Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.CrossRefPubMed
9.
go back to reference Goretzki PE, Mogl MT, Akca A, Pratschke J. Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract. Rev Endocr Metab Disord. 2018;19(2):169–78.CrossRefPubMed Goretzki PE, Mogl MT, Akca A, Pratschke J. Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract. Rev Endocr Metab Disord. 2018;19(2):169–78.CrossRefPubMed
10.
go back to reference Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37.CrossRefPubMed Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37.CrossRefPubMed
11.
go back to reference Tierney JF, Chivukula SV, Wang X, Pappas SG, Schadde E, Hertl M, et al. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2019;165(3):644–51.CrossRefPubMed Tierney JF, Chivukula SV, Wang X, Pappas SG, Schadde E, Hertl M, et al. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2019;165(3):644–51.CrossRefPubMed
12.
go back to reference Bertani E, Zugni F, Radice D, Spada F, Bonomo G, Fumagalli Romario U, et al. Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors. Updat Surg. 2022;74(5):1697–704.CrossRef Bertani E, Zugni F, Radice D, Spada F, Bonomo G, Fumagalli Romario U, et al. Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors. Updat Surg. 2022;74(5):1697–704.CrossRef
13.
go back to reference Lewis A, Raoof M, Ituarte PHG, Williams J, Melstrom L, Li D, et al. Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment. Ann Surg. 2019;270(6):1131–7.CrossRefPubMed Lewis A, Raoof M, Ituarte PHG, Williams J, Melstrom L, Li D, et al. Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment. Ann Surg. 2019;270(6):1131–7.CrossRefPubMed
14.
go back to reference Zheng M, Li Y, Li T, Zhang L, Zhou L. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: a SEER-based analysis. Cancer Med. 2019;8(11):5128–36.CrossRefPubMedPubMedCentral Zheng M, Li Y, Li T, Zhang L, Zhou L. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: a SEER-based analysis. Cancer Med. 2019;8(11):5128–36.CrossRefPubMedPubMedCentral
15.
go back to reference Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al. ENETS consensus guidelines for high-grade Gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94.CrossRefPubMed Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al. ENETS consensus guidelines for high-grade Gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94.CrossRefPubMed
16.
go back to reference Felder S, Jann H, Arsenic R, Denecke T, Prasad V, Knappe-Drzikova B, et al. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocr Relat Cancer. 2019;26(9):751–63.CrossRefPubMedPubMedCentral Felder S, Jann H, Arsenic R, Denecke T, Prasad V, Knappe-Drzikova B, et al. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocr Relat Cancer. 2019;26(9):751–63.CrossRefPubMedPubMedCentral
17.
go back to reference Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(7):839–68.CrossRef Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(7):839–68.CrossRef
18.
go back to reference Li Z, Ren H, Wang T, Zhang X, Zhao L, Sun C, et al. Resection of the primary tumor improves the survival of patients with stage IV gastric neuroendocrine carcinoma. Front Oncol. 2022;12:930491.CrossRefPubMedPubMedCentral Li Z, Ren H, Wang T, Zhang X, Zhao L, Sun C, et al. Resection of the primary tumor improves the survival of patients with stage IV gastric neuroendocrine carcinoma. Front Oncol. 2022;12:930491.CrossRefPubMedPubMedCentral
19.
go back to reference Selberherr A, Freermann S, Koperek O, Niederle MB, Riss P, Scheuba C, Niederle B. Neuroendocrine liver metastasis from the small intestine: is surgery beneficial for survival? Orphanet J Rare Dis. 2021;16(1):30.CrossRefPubMedPubMedCentral Selberherr A, Freermann S, Koperek O, Niederle MB, Riss P, Scheuba C, Niederle B. Neuroendocrine liver metastasis from the small intestine: is surgery beneficial for survival? Orphanet J Rare Dis. 2021;16(1):30.CrossRefPubMedPubMedCentral
20.
go back to reference Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, Tiensuu Janson E, et al. Association of a Prophylactic Surgical Approach to stage IV small intestinal neuroendocrine tumors with survival. JAMA Oncol. 2018;4(2):183–9.CrossRefPubMed Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, Tiensuu Janson E, et al. Association of a Prophylactic Surgical Approach to stage IV small intestinal neuroendocrine tumors with survival. JAMA Oncol. 2018;4(2):183–9.CrossRefPubMed
21.
go back to reference Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16(3):885–94.CrossRefPubMed Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16(3):885–94.CrossRefPubMed
22.
go back to reference Sorbye H, Grande E, Pavel M, Tesselaar M, Fazio N, Reed NS, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35(3):e13249.CrossRefPubMed Sorbye H, Grande E, Pavel M, Tesselaar M, Fazio N, Reed NS, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35(3):e13249.CrossRefPubMed
23.
go back to reference Citterio D, Pusceddu S, Facciorusso A, Coppa J, Milione M, Buzzoni R, et al. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. Eur J Surg Oncol. 2017;43(2):380–7.CrossRefPubMed Citterio D, Pusceddu S, Facciorusso A, Coppa J, Milione M, Buzzoni R, et al. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. Eur J Surg Oncol. 2017;43(2):380–7.CrossRefPubMed
24.
go back to reference Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, et al. Surgery for pancreatic neuroendocrine tumor G3 and carcinoma G3 should be considered separately. Ann Surg Oncol. 2019;26(5):1385–93.CrossRefPubMed Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, et al. Surgery for pancreatic neuroendocrine tumor G3 and carcinoma G3 should be considered separately. Ann Surg Oncol. 2019;26(5):1385–93.CrossRefPubMed
25.
go back to reference Rossi RE, Corti F, Pusceddu S, Milione M, Coppa J, Masoni B, et al. Multidisciplinary approach to the diagnosis of occult primary neuroendocrine neoplasm: a clinical challenge. J Clin Med. 2023;12(17). Rossi RE, Corti F, Pusceddu S, Milione M, Coppa J, Masoni B, et al. Multidisciplinary approach to the diagnosis of occult primary neuroendocrine neoplasm: a clinical challenge. J Clin Med. 2023;12(17).
26.
go back to reference Gangi A, Manguso N, Gong J, Crystal JS, Paski SC, Hendifar AE, Tuli R. Midgut neuroendocrine tumors with liver-only metastases: benefit of primary tumor resection. Ann Surg Oncol. 2020;27(11):4525–32.CrossRefPubMed Gangi A, Manguso N, Gong J, Crystal JS, Paski SC, Hendifar AE, Tuli R. Midgut neuroendocrine tumors with liver-only metastases: benefit of primary tumor resection. Ann Surg Oncol. 2020;27(11):4525–32.CrossRefPubMed
27.
go back to reference Lin J, Zhao Y, Zhou Y, Tian Y, He Q, Lin J, et al. Comparison of survival and patterns of recurrence in gastric neuroendocrine carcinoma, mixed Adenoneuroendocrine carcinoma, and adenocarcinoma. JAMA Netw Open. 2021;4(7):e2114180.CrossRefPubMedPubMedCentral Lin J, Zhao Y, Zhou Y, Tian Y, He Q, Lin J, et al. Comparison of survival and patterns of recurrence in gastric neuroendocrine carcinoma, mixed Adenoneuroendocrine carcinoma, and adenocarcinoma. JAMA Netw Open. 2021;4(7):e2114180.CrossRefPubMedPubMedCentral
28.
go back to reference Kidd M, Modlin I, Öberg K. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat Rev Clin Oncol. 2016;13(11):691–705.CrossRefPubMed Kidd M, Modlin I, Öberg K. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat Rev Clin Oncol. 2016;13(11):691–705.CrossRefPubMed
29.
go back to reference Mosquera C, Koutlas NJ, Fitzgerald TL. Localized high-grade gastroenteropancreatic neuroendocrine tumors: defining prognostic and therapeutic factors for a disease of increasing clinical significance. Eur J Surg Oncol. 2016;42(10):1471–7.CrossRefPubMed Mosquera C, Koutlas NJ, Fitzgerald TL. Localized high-grade gastroenteropancreatic neuroendocrine tumors: defining prognostic and therapeutic factors for a disease of increasing clinical significance. Eur J Surg Oncol. 2016;42(10):1471–7.CrossRefPubMed
30.
go back to reference Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, et al. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut. 2021;70(9):1768–81.CrossRefPubMed Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, et al. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut. 2021;70(9):1768–81.CrossRefPubMed
32.
go back to reference Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54.CrossRefPubMed Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54.CrossRefPubMed
33.
go back to reference Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.CrossRefPubMed Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.CrossRefPubMed
35.
go back to reference Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153-RR63.CrossRefPubMed Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153-RR63.CrossRefPubMed
36.
go back to reference Le Treut YP, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant. 2008;8(6):1205–13.CrossRefPubMed Le Treut YP, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant. 2008;8(6):1205–13.CrossRefPubMed
37.
go back to reference Dhupar R, de Vera ME, Marsh JW, Fontes PA, Steel JL, Zeh HJ, Gamblin TC. Simultaneous pancreatectomy and liver transplantation: a single-institution experience. HPB (Oxford). 2009;11(3):242–6.CrossRefPubMedPubMedCentral Dhupar R, de Vera ME, Marsh JW, Fontes PA, Steel JL, Zeh HJ, Gamblin TC. Simultaneous pancreatectomy and liver transplantation: a single-institution experience. HPB (Oxford). 2009;11(3):242–6.CrossRefPubMedPubMedCentral
38.
39.
go back to reference Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch. 2018;472(3):341–9.CrossRefPubMed Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch. 2018;472(3):341–9.CrossRefPubMed
40.
go back to reference Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer. 2012;48(11):1608–15.CrossRefPubMed Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer. 2012;48(11):1608–15.CrossRefPubMed
41.
go back to reference Lanari J, Hagness M, Sartori A, Rosso E, Gringeri E, Dueland S, et al. Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score. Transpl Int. 2021;34(9):1722–32.CrossRefPubMed Lanari J, Hagness M, Sartori A, Rosso E, Gringeri E, Dueland S, et al. Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score. Transpl Int. 2021;34(9):1722–32.CrossRefPubMed
42.
go back to reference Siriwardena AK, Mason JM, Mullamitha S, Hancock HC, Jegatheeswaran S. Management of colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol. 2014;11(8):446–59.CrossRefPubMed Siriwardena AK, Mason JM, Mullamitha S, Hancock HC, Jegatheeswaran S. Management of colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol. 2014;11(8):446–59.CrossRefPubMed
43.
go back to reference Chen J-N, Shoucair S, Wang Z, Habib JR, Zhao F-Q, Yu J, et al. Primary tumor resection for rectal Cancer with Unresectable liver metastases: a chance to cut is a chance for improved survival. Front Oncol. 2021;11:628715.CrossRefPubMedPubMedCentral Chen J-N, Shoucair S, Wang Z, Habib JR, Zhao F-Q, Yu J, et al. Primary tumor resection for rectal Cancer with Unresectable liver metastases: a chance to cut is a chance for improved survival. Front Oncol. 2021;11:628715.CrossRefPubMedPubMedCentral
44.
go back to reference Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, et al. Long term efficacy and assessment of tumor response of Transarterial chemoembolization in neuroendocrine liver metastases: a 15-year monocentric experience. Cancers (Basel). 2021;13(21). Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, et al. Long term efficacy and assessment of tumor response of Transarterial chemoembolization in neuroendocrine liver metastases: a 15-year monocentric experience. Cancers (Basel). 2021;13(21).
45.
go back to reference Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177–82.CrossRefPubMed Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177–82.CrossRefPubMed
Metadata
Title
Resection of the primary tumor improves the prognosis of gastrointestinal neuroendocrine neoplasms with liver metastases: mutual validation based on SEER database and institutional data
Authors
Yifan Liu
Zhixiong Wang
Qi Lin
Ruizhe Cui
Wei Tang
Guanghua Li
Zhao Wang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-03041-6

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.